<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03095339</url>
  </required_header>
  <id_info>
    <org_study_id>1419</org_study_id>
    <nct_id>NCT03095339</nct_id>
  </id_info>
  <brief_title>EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso</brief_title>
  <acronym>EFECAB</acronym>
  <official_title>EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AFRICSanté</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherche en Sciences de la Sante, Burkina Faso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ouagadougou, Burkina Faso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Universitaire Souro Sanou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pre-post randomized community-based controlled trial aimed at estimating the
      effectiveness of an educational package developed using PRECEDE PROCEED to reduce the
      cumulative incidence of Taenia solium cysticercosis in three Provinces of Burkina Faso. The
      study design included an 18-months baseline study to measure baseline cumulative incidence of
      cysticercosis followed by an 18-month post randomization study to measure the effectiveness
      of the intervention. Sixty villages of three Provinces of Burkina Faso were included. The
      primary outcome was the change in the baseline to post randomization cumulative incidence in
      the intervention group compared to the control group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2011</start_date>
  <completion_date type="Actual">January 31, 2015</completion_date>
  <primary_completion_date type="Actual">November 24, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a pre-post community-based randomized controlled trial. The unit of randomization is the village (community)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Human active cysticercosis cumulative incidence</measure>
    <time_frame>baseline, 18 months follow-up pre randomization, 18 months follow-up post randomization</time_frame>
    <description>Sero conversion to the AgELISA test to detect antigens of cysticercosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Porcine active cysticercosis prevalence</measure>
    <time_frame>baseline, 18 months follow-up pre randomization, 18 months follow-up post randomization</time_frame>
    <description>Sero-positivity to the AgELISA test to detect antigens of cysticercosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in knowledge, attitude and practices</measure>
    <time_frame>baseline, 18 months follow-up pre randomization, 18 months follow-up post randomization</time_frame>
    <description>Change in answers to the questionnaire through time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of epilepsy and progressively worsening severe chronic headaches</measure>
    <time_frame>baseline, 18 months follow-up pre randomization, 18 months follow-up post randomization</time_frame>
    <description>development of neurological disorders among those followed up at least twice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stigmatization of epilepsy</measure>
    <time_frame>18 months follow-up post randomization</time_frame>
    <description>Attitudes and knowledge regarding epilepsy post randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Cysticercosis</condition>
  <arm_group>
    <arm_group_label>Educational package</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The educational package included the offering of the Self-Esteem , Associative strengths, Resourcefulness, Action-planning and Responsibility (SARAR) Participatory Hygiene and Sanitation Transformation (PHAST) approach, a 52 minutes educational movie and accompanying cartoon booklet. The package was developed using the PRECEDE approach.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group did not receive any intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Educational package</intervention_name>
    <description>The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.</description>
    <arm_group_label>Educational package</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The unit of randomization and analysis of this study is the village. Therefore, the
        eligibility criteria were determined at the village level.

        Inclusion Criteria:

          -  Population of at least 1000 at the 2006 census

          -  Present on the map of the &quot;Institut Géographique du Burkina 2000&quot;

          -  Separated from another village by at least 5 kilometers.

        Exclusion Criteria:

          -  Village located on a National or Provincial road

          -  Village located within 20 km of Koudougou or Ouagadougou

          -  Regional or Provincial Capital

          -  Absence of pigs in the village

        At the individual level, the following eligibility criteria were used:

        Inclusion Criteria:

          -  Aged 5 years old or more

          -  Has lived in the village for at least 12 months

          -  Not planning to move in the next three years

        Exclusion Criteria:

          -  Presence of confirmed epilepsy or progressively worsening severe chronic headaches at
             baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène Carabin, DVM PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AFRICSanté</name>
      <address>
        <city>Bobo Dioulasso</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <link>
    <url>http://africsante.org/</url>
    <description>Website of the facility in Burkina Faso which managed the study</description>
  </link>
  <reference>
    <citation>Carabin H, Traoré AA. Taenia solium taeniasis and cysticercosis control and elimination through community-based interventions. Curr Trop Med Rep. 2014 Dec 1;1(4):181-193.</citation>
    <PMID>25544938</PMID>
  </reference>
  <reference>
    <citation>Nitiéma P, Carabin H, Hounton S, Praet N, Cowan LD, Ganaba R, Kompaoré C, Tarnagda Z, Dorny P, Millogo A, Efécab. Prevalence case-control study of epilepsy in three Burkina Faso villages. Acta Neurol Scand. 2012 Oct;126(4):270-8. doi: 10.1111/j.1600-0404.2011.01639.x. Epub 2012 Jan 31.</citation>
    <PMID>22289127</PMID>
  </reference>
  <reference>
    <citation>John CC, Carabin H, Montano SM, Bangirana P, Zunt JR, Peterson PK. Global research priorities for infections that affect the nervous system. Nature. 2015 Nov 19;527(7578):S178-86. doi: 10.1038/nature16033. Review.</citation>
    <PMID>26580325</PMID>
  </reference>
  <reference>
    <citation>Carabin H, Millogo A, Cissé A, Gabriël S, Sahlu I, Dorny P, Bauer C, Tarnagda Z, Cowan LD, Ganaba R. Prevalence of and Factors Associated with Human Cysticercosis in 60 Villages in Three Provinces of Burkina Faso. PLoS Negl Trop Dis. 2015 Nov 20;9(11):e0004248. doi: 10.1371/journal.pntd.0004248. eCollection 2015 Nov.</citation>
    <PMID>26588468</PMID>
  </reference>
  <reference>
    <citation>Dermauw V, Ganaba R, Cissé A, Ouedraogo B, Millogo A, Tarnagda Z, Van Hul A, Gabriël S, Carabin H, Dorny P. Taenia hydatigena in pigs in Burkina Faso: A cross-sectional abattoir study. Vet Parasitol. 2016 Oct 30;230:9-13. doi: 10.1016/j.vetpar.2016.10.022. Epub 2016 Oct 24.</citation>
    <PMID>27884445</PMID>
  </reference>
  <reference>
    <citation>Carabin H, Winkler AS, Dorny P. Taenia solium cysticercosis and taeniosis: Achievements from the past 10 years and the way forward. PLoS Negl Trop Dis. 2017 Apr 20;11(4):e0005478. doi: 10.1371/journal.pntd.0005478. eCollection 2017 Apr.</citation>
    <PMID>28426664</PMID>
  </reference>
  <results_reference>
    <citation>Ngowi H, Ozbolt I, Millogo A, Dermauw V, Somé T, Spicer P, Jervis LL, Ganaba R, Gabriel S, Dorny P, Carabin H. Development of a health education intervention strategy using an implementation research method to control taeniasis and cysticercosis in Burkina Faso. Infect Dis Poverty. 2017 Jun 1;6(1):95. doi: 10.1186/s40249-017-0308-0.</citation>
    <PMID>28569208</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burkina Faso</keyword>
  <keyword>Community-based randomized controlled trial</keyword>
  <keyword>Cysticercosis</keyword>
  <keyword>Implementation Research</keyword>
  <keyword>Effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Cysticercosis</mesh_term>
    <mesh_term>Taeniasis</mesh_term>
    <mesh_term>Neurocysticercosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data will be made available at the time of publication as per NIH requirements</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

